GlassScriptPhysician profile
Jeffrey S Nelson
NPI 1952444788
$10,945.32
in general payments reported to CMS, 2019-2025
40 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $1,119 · 2021: $1,350 · 2022: $1,746 · 2023: $1,414 · 2024: $2,172 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,413 · Education: $54.95 · Consulting Fee: $13.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,413.12 |
| Education | $54.95 |
| Consulting Fee | $13.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,681.27 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,446.48 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Grifols USA, LLC | $961.03 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genzyme Corporation | $937.52 | 2019-2025 | |
| Pharming Healthcare, INC. | $794.35 | 2019-2025 | Ruconest |
| Genentech USA, INC. | $657.44 | 2019-2025 | Xolair |
| Csl Behring | $589.08 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $574.40 | 2020-2025 | Eohilia, Takhzyro, Gattex |
| Pfizer INC. | $406.06 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $356.42 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $289.20 | 2021-2024 | Orladeyo |
| Abbvie INC. | $193.70 | 2022-2024 | |
| Ars Pharmaceuticals Operations, INC. | $176.14 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $175.92 | 2019-2025 | Dupixent |
| Octapharma USA, INC. | $165.43 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $161.67 | 2019-2023 | Airduo Digihaler |
| Optinose US, INC. | $139.35 | 2019-2025 | |
| Alk-Abello, INC | $134.37 | 2019-2022 | |
| Hospira, INC. | $125.28 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $109.28 | 2021-2025 | |
| Horizon Therapeutics Plc | $105.02 | 2020-2022 | |
| Shire North American Group INC | $91.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.46 | 2019-2020 | |
| Amgen INC. | $66.16 | 2024-2025 | Tezspire |
| Kaleo, INC. | $55.84 | 2019-2021 | |
| Bio Products Laboratory USA, INC. | $54.61 | 2022-2023 | Gammaplex, Coagadex |
| Leo Pharma INC. | $50.02 | 2022 | |
| Galderma Laboratories, L.P. | $47.56 | 2024-2025 | Nemluvio |
| Covis Pharma Gmbh | $46.62 | 2021 | |
| Ionis Pharmaceuticals, INC. | $44.25 | 2025 | Dawnzera |
| Jazz Pharmaceuticals INC. | $38.28 | 2019 | |
| Organon LLC | $34.92 | 2025 | Vtama |
| Blueprint Medicines Corporation | $33.26 | 2024 | Ayvakit |
| Seqirus USA INC | $31.40 | 2021-2025 | Flucelvax |
| Gc Biopharma USA, INC. | $23.14 | 2025 | Alyglo |
| Lilly USA, LLC | $20.65 | 2024 | Ebglyss |
| Mylan Specialty L.P. | $18.71 | 2020 | |
| Circassia INC. | $14.26 | 2019 | |
| Uswm, LLC | $14.00 | 2021 | |
| Adma Biomanufacturing LLC | $13.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.